Plate Nº 83 · recorded November 18, 2026
Biology & EvolutionReported finding
Staph Enzyme LytU Boosts Vancomycin Resistance 30-Fold in Lab Tests
A Finnish team found the enzyme LytU breaks an unusual bond in staph's cell wall, and bacteria making more of it were 30 times more resistant to vancomycin.
By Elena Vasquez3 min read565 words
In brief
- Bacteria overproducing LytU showed roughly 30-fold higher resistance to vancomycin in lab experiments.
- The study, led by Professor Perttu Permi, was published in Nature Communications (DOI: 10.1038/s41467-026-78872-4).
- Researchers came from the universities of Jyväskylä and Helsinki in Finland.
- LytU breaks a specific bridge bond in cell-wall cross-linking, unlike other enzymes in its family.
- Clinical relevance remains unproven; further studies in patient isolates are needed.

Bacteria engineered to produce more of an enzyme called LytU were roughly 30 times more resistant to the last-resort antibiotic vancomycin, researchers at the universities of Jyväskylä and Helsinki report. The finding, published in Nature Communications, exposes a previously unknown way that Staphylococcus aureus rebuilds its protective cell wall under antibiotic pressure.
The study, led by Professor Perttu Permi of the University of Jyväskylä, focused on how this dangerous human pathogen adapts when doctors reach for one of medicine's final options.
Why does vancomycin matter?
Staphylococcus aureus is notorious for acquiring resistance to multiple antibiotics. Vancomycin is commonly used to treat serious infections caused by resistant staphylococci, which makes any new resistance mechanism a clinical concern. Antimicrobial resistance as a whole ranks among the biggest challenges facing modern medicine, and bacteria that defeat last-line drugs worry researchers most.
The new work points to a single enzyme as a possible lever in that fight. That lever sits in the cell wall, the complex outer structure that shields bacteria from external stress, maintains cell shape, and serves as the target for many antibiotics. Its main building block is peptidoglycan, a mesh-like molecule that gives the wall its strength.
What does LytU actually do?
The team examined LytU, an enzyme involved in modifying the cell wall, and found it behaves unlike any known relative. "To our surprise, LytU did not behave like other known proteins belonging to the same enzyme family," Permi said. "Instead of cutting the usual bonds in peptidoglycan, it broke a specific bridge bond in the cell wall structure that plays a key role in cell wall cross-linking."
In plain terms, LytU snips a different link than its enzyme family normally does, altering how the wall's structural strands connect to each other. That single change can shift how well antibiotics work, because the results show minor modifications to cell-wall structure affect antibiotic activity.
How strong is the resistance effect?
In the researchers' experiments, bacteria producing more LytU were about 30 times more resistant to vancomycin than control bacteria. But the mechanism has limits. LytU activity must be tightly regulated: while increased expression can enhance resistance, excessive enzyme activity disrupts normal cell-wall construction.
"What makes this discovery particularly exciting is that we have identified an enzyme that connects two seemingly opposing processes: bacterial cell-wall remodeling and antibiotic resistance," Permi said. "It gives us a new perspective on how Staphylococcus aureus adapts its cell wall in response to antibiotic stress."
What are the caveats?
The experiments were lab-based, and the researchers themselves flag the limits. Further studies are needed to establish how much LytU contributes to antibiotic resistance in clinical isolates and adapted resistant strains, meaning bacteria taken from real patients rather than laboratory conditions. A 30-fold effect in a controlled experiment does not automatically translate to harder-to-treat infections in hospitals.
Still, the discovery opens a door. "This discovery provides a new molecular perspective on the relationship between cell-wall remodeling and antimicrobial resistance," Permi explained.
The results offer researchers a fresh view of bacterial defense mechanisms and may help develop new strategies to fight antibiotic resistance in the future. In short: one enzyme, one unusual bond, and a clearer picture of how staph fights back.
The paper, by Lina Antenucci and colleagues, appears in Nature Communications (DOI: 10.1038/s41467-026-78872-4).
via phys.org/rss-feed/ (Source)
More from Elena Vasquez
Show full bio
Correspondent covering money, funding and market shifts around general science news at SciBeat.
503 articles
Nearby plates
- Stable Genes, Not Shuffling, Made a Superbug Dominant — Then It Fell
- Staph Bacteria Grows Three Times Thicker Cell Wall in Milk, Study Finds
- Two Protein Plugs Help Superbug P. aeruginosa Block Antibiotics
- Evolved Enzymes Build TB Antibiotic Ingredient Without the Waste
- Scientists identify first PLP-dependent tRNA-modifying enzyme